IntelGenx enters development, license agreement for VetaFilm

IntelGenx has entered into development and license agreements with a wholly-owned subsidiary of Covenant Animal Health Partners. Under the terms of the development agreement, Covenant Animal Health will fund development and manufacturing of a VetaFilm-based drug. The license agreement will give Covenant Animal Health exclusive rights to exploit the Product in the field for non-human applications. In return, IntelGenx will receive royalties on worldwide net sales of the Product. IntelGenx will manufacture the Product on worldwide basis for clinical development, and the parties anticipate entering into a subsequent commercial supply agreement, pursuant to which IntelGenx will supply the Product to Covenant Animal Health.